Thursday, October 25, 2018 10:30:37 AM
Shows the progress Pluristem has made, with P3 clinical trials, greater and greater understanding of the process of "training" (1) MSCs to specialize for specific indications, establishing partnerships to help in making PLX-PAD available in massive quantities, expanding an already rich patent portfolio, etc., ... all good!
1. training = induction, "Advancement of these therapies relies on the ability to direct MSCs toward specific cell phenotypes."
That's what Pluristem's scientists and academic collaborators have been doing for the last few years. That's how you get to radically new therapeutic modalities!
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM